# Jose Antonio Lopez Valverde Postdoctoral Research Fellow, Department of Radiation Oncology, Dana Farber Cancer Institute/Brigham and Women's Hospital & Massachusetts General Hospital - Harvard Medical School ![pie](/sites/g/files/omnuum986/files/styles/hwp_4_5__480x600/public/2025-02/Jose-Antonio-Lopez-Valverde-Copy.png?itok=WXLP7W_3) email Jose Antonio Lopez Valverde joined the RCC as a Postdoctoral Research Fellow in September 2024. He holds a PhD in Molecular Biology, Biomedicine and Clinical Research from the University of Seville. He also holds a BSc in Biomedical Sciences, a BSc in Biochemistry, and an MSc in Biomedical Research. He was awarded an FPU research fellowship to carry out his doctoral studies in the Medical Physiology and Biophysics Department of the University of Seville, where he specialized in medical physics, in the field of radiosensitizing nanoparticles. His thesis focused on the evaluation of gold nanoparticles as theragnostic agents in radiotherapy under realistic clinical conditions, performing research in different areas such as radiobiology experimentation, computational modeling of radiotherapy, and nanoparticle synthesis and characterization. This research was carried out at the Medical Physics Laboratory of the University of Seville, hosted by Prof. Antonio Leal. During this period, his training was further broadened when he joined Harvard Medical School for an academic semester, where he further specialized in radiotherapy computational modeling tools and performed experimentation with nanoparticles, benchmarking gold-based nanoparticles with AGuIX®, one of the nanoparticle solutions that is already under clinical trials. He has been awarded an RCC postdoctoral fellowship to join Harvard Medical School-associated laboratories of Prof. Ross Berbeco at Dana Farber Cancer Institute/Brigham and Women's Hospital, and Prof. Alejandro Bertolet at Massachusetts General Hospital. His main project focuses on studying and characterizing the internalization dynamics of radiosensitizing nanoparticles, and how they affect the mechanism of action of such nanoparticles. Ultimately, this research aims to improve the tumor control and the response of radiotherapy treatments.